论文部分内容阅读
目的探讨DSG-3型生物信息红外肝病治疗仪联合当飞利肝宁胶囊治疗非酒精性脂肪性肝病的临床疗效。方法将非酒精性脂肪性肝病患者98例随机分为两组，治疗组给予DSG-3型生物信息红外肝病治疗仪及当飞利肝宁胶囊治疗，对照组仅给予当飞利肝宁胶囊口服。共治疗12周。观察两组患者症状、肝功能、血脂及肝脏彩超影像学改变。结果治疗组症状、肝功能、血脂、肝脏彩超影像学等指标改善与对照组比较均有显著性差异（P<0.05）。结论DSG-3型生物信息红外肝病治疗仪联合当飞利肝宁胶囊治疗非酒精性脂肪性肝病效果显著，优于单纯药物治疗。“,” Objective: To investigate the clinical therapeutic effectiveness on non-alcoholic fatty liver disease(NAFLD) treated by DSG-3-type of bioinformatics infrared liver disease therapy instrument combined with Dangfeiliganning capsule. Methods: 98 cases of patients with non-alcoholic fatty liver disease were randomly divided into two groups, the treatment group received DSG-3 type bioinformatics infrared liver disease therapy instrument and Dangfeiliganning capsule, the control group were given only Dangfeiliganning capsule oraly. To observe the two treatment groups of patients in symptoms, liver function, blood lipids, and changes in the liver color Doppler imaging after a total of 12 weeks of treatment. Results: In comparison with the control group, the treatment group showed a significant difference (P <0.05) in symptoms, liver function, blood lipids, liver ultrasonography imaging and other indicators of improvement. Conclusion: The treatment effect of DSG-3 type bioinformatics infrared liver disease therapy instrument combined with Dangfeiliganning Capsule of non-alcoholic fatty liver disease is significantly better than simple drug treatment.